AI assistant
BIOTRON LIMITED — Capital/Financing Update 2025
Mar 12, 2025
64528_rns_2025-03-12_3fc7b46d-a814-4ebe-b792-799f66b8203e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [230 x 35] intentionally omitted <==
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: [email protected] Website: www.biotron.com.au
13 March 2025
The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000
(2 pages by email)
Dear Madam
UPDATE ON RIGHTS ISSUE TIMETABLE ASX: BITR
Biotron Limited ( ASX:BIT ) ( Biotron or the Company ) refers to rights issue announced to the ASX on 28 February 2025 and for which the Company lodged a prospectus with ASIC on 3 March 2025 ( Rights Issue ).
Following queries by ASIC and ASX, on 12 March 2025 the Company lodged a replacement prospectus with ASIC and announced to the ASX that day. Following is an updated timetable for the Rights Issue:
| Prospectus with Entitlement and Acceptance Form sent to EligibleShareholders | 18 March 2025 |
|---|---|
| Offer opens for receipt of Applications | 18 March 2025 |
| Rights trading ends at close of trading | 25 March 2025 |
| Unless otherwise determined by ASX, new shares quoted on a deferredsettlement basis from market open. | 26 March 2025 |
| Latest date to extend the Rights Issue | 27 March 2025 |
| Closing date for acceptances | 5pm AEDT 1 April 2025 |
| Announce results of the Rights Issue | 8 April 2025 |
| Issue of New Shares | 8 April 2025 |
| Normal trading of New Shares expected to commence | 9 April 2025 |
| Dispatch of shareholding statements | 10 April 2025 |
| Last date to issue Shortfall Shares | 1 July 2025 |
Note: The Directors may extend the Closing Date by giving at least 3 Business Days’ notice to ASX prior to the Closing Date, subject to such date being no later than 3 months after the date of the Prospectus. As such the date the New Shares are expected to commence trading on ASX may vary.
1
Eligible Shareholders may take up shortfall in addition to their entitlements under the Rights Issue. Applications for securities under the Rights Issue can be made via BPAY® by following the instructions set out in the personalised Entitlement and Acceptance Form that will be sent to Eligible Shareholders with the prospectus. Persons should consider the prospectus in deciding whether to acquire securities under the Rights Issue.
For more information please contact:
Enquiries: Dr Michelle Miller Peter Nightingale Managing Director Company Secretary +61-(0) 41231 3329 +(612) 9300 3344
This announcement has been authorised for release to the market by the Managing Director.
Yours sincerely
==> picture [110 x 71] intentionally omitted <==
Peter J. Nightingale Company Secretary
pjn12558
2